Recarbrio us market launch date?

Recarbrio (imipenem/cilastatin/relebactam) was approved by the U.S. FDA on July 17, 2019. The product then launched in the U.S. later in 2019, with the initial U.S. rollout starting in late summer (roughly August–September 2019). If you’d like, I can look up the exact first sale/shipment date.